Nath Bio-Genes

{
  "main_header": {
    "sid": 628630,
    "name": "Nath Bio-Genes",
    "stock_name": "Nath Bio-Genes",
    "full_name": "Nath Bio-Genes (India) Ltd",
    "name_url": "stocks-analysis/nath-bio-genes",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "145.35",
    "chg": 2.15,
    "chgp": "1.5%",
    "dir": 1,
    "prev_price": "143.20",
    "mcapval": "271.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 537291,
    "symbol": "NATHBIOGEN",
    "ind_name": "Other Agricultural Products",
    "ind_code": 107,
    "indexname": "",
    "isin": "INE448G01010",
    "curr_date": "Jan 30",
    "curr_time": "",
    "bse_nse_vol": "15.2 k",
    "exc_status": "Active",
    "traded_date": "Jan 30, 2026",
    "traded_date_str": "2026 01 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nath-bio-genes-628630-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Nath Bio-Genes (India) Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-nath-bio-genes-india-ltd-latest-results-good-or-bad-3813334",
        "imagepath": "",
        "date": "2026-01-31 19:23:06",
        "description": "Nath Bio-Genes (India) Ltd's latest financial results reveal a complex picture of operational performance marked by significant volatility. In the quarter ended September 2025, the company reported net sales of ₹43.85 crores, which reflects a notable year-on-year growth of 36.22% compared to ₹32.19 crores in the same quarter last year. However, this figure represents a substantial decline of 84.54% from the preceding quarter's sales of ₹283.70 crores, highlighting the seasonality inherent in its agricultural products business.\n\nThe net profit for the same quarter was ₹2.75 crores, showing a remarkable year-on-year increase of 147.75% from ₹1.11 crores in Q2 FY25. Conversely, it experienced a sharp decline of 92.62% compared to the previous quarter's profit of ₹37.28 crores. This extreme fluctuation underscores the challenges in assessing the company's performance on a quarter-to-quarter basis.\n\nThe operatin..."
      },
      {
        "title": "Nath Bio-Genes Q3 FY26: Seasonal Surge Masks Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/nath-bio-genes-q3-fy26-seasonal-surge-masks-profitability-concerns-3813264",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_quaterlyResult_3813264.png",
        "date": "2026-01-31 18:31:39",
        "description": "Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹271.00 crores, reported a consolidated net profit of ₹1.60 crores for Q3 FY26 (October-December 2025), representing a sharp 66.80% decline quarter-on-quarter and a 39.62% fall year-on-year. Despite a robust 78.90% YoY revenue increase to ₹65.96 crores driven by seasonal demand, the company's profitability deteriorated significantly as operating margins compressed and interest costs surged to their highest quarterly levels."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-strong-sell-3805186",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_mojoScore_3805186.png",
        "date": "2026-01-27 10:10:49",
        "description": "Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 January 2026, providing investors with the latest perspective on the company’s performance and prospects."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd Hits 52-Week Low Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nath-bio-genes-india-ltd-hits-52-week-low-amidst-continued-downtrend-3796734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_priceRelatedfactors_3796734.png",
        "date": "2026-01-20 15:15:43",
        "description": "Nath Bio-Genes (India) Ltd’s shares declined sharply to a new 52-week low of Rs.139.8 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock underperformed its sector and key market indices, reflecting ongoing concerns about the company’s financial performance and investor sentiment."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvements and Valuation Appeal",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-upgraded-to-sell-on-technical-improvements-and-valuation-appeal-3781070",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_mojoScore_3781070.png",
        "date": "2026-01-05 08:11:14",
        "description": "Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 January 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid mixed financial and market signals."
      },
      {
        "title": "Nath Bio-Genes (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-india-ltd-is-rated-sell-3779836",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NathBioGenesInd_mojoScore_3779836.png",
        "date": "2026-01-03 10:10:34",
        "description": "Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 January 2026, providing investors with the most recent and relevant data to assess the company's outlook."
      },
      {
        "title": "Nath Bio-Genes (India) Faces Challenging Market Assessment Amidst Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nath-bio-genes-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3766672",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NathBioGenesInd_mojoScore_3766672.png",
        "date": "2025-12-23 08:45:09",
        "description": "Nath Bio-Genes (India), a player in the Other Agricultural Products sector, has experienced a shift in market evaluation driven by a combination of technical indicators, valuation metrics, financial trends, and broader market participation. This article analyses the factors influencing the recent revision in the company’s assessment, highlighting key data points and contextualising its performance against sector and market benchmarks."
      },
      {
        "title": "Why is Nath Bio-Genes falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-nath-bio-genes-fallingrising-3749560",
        "imagepath": "",
        "date": "2025-12-06 01:25:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>On 05-Dec, Nath Bio-Genes closed at ₹142.45, down by ₹3.4 or 2.33%, marking a continuation of a downward trend that has persisted over the last four trading sessions. During this period, the stock has lost nearly 9.84% in value, hitting a fresh 52-week low of ₹140.1 intraday. This decline is further accentuated by the stock’s underperformance against its sector, lagging by 3.08% on the day. The weighted average price indicates that a significant volume of shares traded closer to the day’s low, signalling selling pressure among investors.</p>\n<p>Moreover, Nath Bio-Genes is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish sentiment prevailing..."
      },
      {
        "title": "Nath Bio-Genes (India) Stock Hits 52-Week Low at Rs.140.1 Amidst Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nath-bio-genes-india-stock-hits-52-week-low-amidst-continued-downtrend-3749224",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NathBioGenesInd_priceRelatedfactors_3749224.png",
        "date": "2025-12-05 15:53:01",
        "description": "Nath Bio-Genes (India) has reached a fresh 52-week low of Rs.140.1, marking a significant decline amid a sustained downward trend over recent sessions. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing pressures within the company’s sector and financial metrics."
      }
    ],
    "total": 139,
    "sid": "628630",
    "stock_news_url": "https://www.marketsmojo.com/news/nath-bio-genes-india-628630"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Approval Of Financial Results As On 31St December 2025.",
      "datetime": "24-Jan-2026",
      "details": "Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2026 inter alia to consider and approve Financial Results as on 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "20-Jan-2026",
      "details": "Compliance Certificate under Reg 74",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "13-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Tapovan Paper and Board Mills Ltd & Others",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "(31 Jan 2026)"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nath Bio-Genes (India) Ltd has declared <strong>20%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Nath Bio-Genes (India) Ltd latest results good or bad?

2026-01-31 19:23:06

Nath Bio-Genes (India) Ltd's latest financial results reveal a complex picture of operational performance marked by significant volatility. In the quarter ended September 2025, the company reported net sales of ₹43.85 crores, which reflects a notable year-on-year growth of 36.22% compared to ₹32.19 crores in the same quarter last year. However, this figure represents a substantial decline of 84.54% from the preceding quarter's sales of ₹283.70 crores, highlighting the seasonality inherent in its agricultural products business. The net profit for the same quarter was ₹2.75 crores, showing a remarkable year-on-year increase of 147.75% from ₹1.11 crores in Q2 FY25. Conversely, it experienced a sharp decline of 92.62% compared to the previous quarter's profit of ₹37.28 crores. This extreme fluctuation underscores the challenges in assessing the company's performance on a quarter-to-quarter basis. The operatin...

Read full news article

Nath Bio-Genes Q3 FY26: Seasonal Surge Masks Profitability Concerns

2026-01-31 18:31:39

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹271.00 crores, reported a consolidated net profit of ₹1.60 crores for Q3 FY26 (October-December 2025), representing a sharp 66.80% decline quarter-on-quarter and a 39.62% fall year-on-year. Despite a robust 78.90% YoY revenue increase to ₹65.96 crores driven by seasonal demand, the company's profitability deteriorated significantly as operating margins compressed and interest costs surged to their highest quarterly levels.

Read full news article

Nath Bio-Genes (India) Ltd is Rated Strong Sell

2026-01-27 10:10:49

Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 January 2026, providing investors with the latest perspective on the company’s performance and prospects.

Read full news article

Nath Bio-Genes (India) Ltd Hits 52-Week Low Amidst Continued Downtrend

2026-01-20 15:15:43

Nath Bio-Genes (India) Ltd’s shares declined sharply to a new 52-week low of Rs.139.8 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock underperformed its sector and key market indices, reflecting ongoing concerns about the company’s financial performance and investor sentiment.

Read full news article

Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvements and Valuation Appeal

2026-01-05 08:11:14

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 January 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid mixed financial and market signals.

Read full news article

Nath Bio-Genes (India) Ltd is Rated Sell

2026-01-03 10:10:34

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 January 2026, providing investors with the most recent and relevant data to assess the company's outlook.

Read full news article

Nath Bio-Genes (India) Faces Challenging Market Assessment Amidst Mixed Financial and Technical Signals

2025-12-23 08:45:09

Nath Bio-Genes (India), a player in the Other Agricultural Products sector, has experienced a shift in market evaluation driven by a combination of technical indicators, valuation metrics, financial trends, and broader market participation. This article analyses the factors influencing the recent revision in the company’s assessment, highlighting key data points and contextualising its performance against sector and market benchmarks.

Read full news article

Why is Nath Bio-Genes falling/rising?

2025-12-06 01:25:11

Recent Price Movement and Market Performance

On 05-Dec, Nath Bio-Genes closed at ₹142.45, down by ₹3.4 or 2.33%, marking a continuation of a downward trend that has persisted over the last four trading sessions. During this period, the stock has lost nearly 9.84% in value, hitting a fresh 52-week low of ₹140.1 intraday. This decline is further accentuated by the stock’s underperformance against its sector, lagging by 3.08% on the day. The weighted average price indicates that a significant volume of shares traded closer to the day’s low, signalling selling pressure among investors.

Moreover, Nath Bio-Genes is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish sentiment prevailing...

Read full news article

Nath Bio-Genes (India) Stock Hits 52-Week Low at Rs.140.1 Amidst Prolonged Downtrend

2025-12-05 15:53:01

Nath Bio-Genes (India) has reached a fresh 52-week low of Rs.140.1, marking a significant decline amid a sustained downward trend over recent sessions. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing pressures within the company’s sector and financial metrics.

Read full news article

View All News